

技術分析



分析師

大中華區研究團隊

research-hk@uobkh.com

譚文漢，特許財務分析師

munhon.tham@uobkh.com

+852 2236 6799

藥明生物 (2269 HK)

最後價格：港幣 57.90 元
 支撐位：港幣 55.40 元/港幣 53.85 元
 阻力位：港幣 62.75 元/港幣 67.75 元

技術分析：

價格行為沿其阻力轉支撐區域執行了成功的回踩試探與結構性防禦，確認了順暢的水平結構極性轉換。**RSI** 指標穩固紮根於強勁的看漲區間，並持續呈現向上斜率傾斜，確認了持續的趨勢速度與多頭衝力拓展。只要價格行為被嚴格防禦在該轉換需求錨點上方，最小阻力路徑將高度傾斜於向更高的主導供給目標方向持續上行拓展。

平均時限：約兩週。

康方生物 (9926 HK)

最後價格：港幣 110.60 元
 支撐位：港幣 103.80 元/港幣 99.10 元
 阻力位：港幣 129.00 元/港幣 141.00 元

技術分析：

價格行為執行了果斷的上行擴張，成功突破了其橫盤盤整區間，隨後沿突破樞軸位完成了回踩試探與結構性防禦。這一成功的回踩確認了水平結構極性的轉換，將前盤整區間的上邊界轉化為首要的結構性需求地基。**RSI** 指標穩固紮根於看漲區間並持續呈現向上斜率傾斜，確認了持續的趨勢速度與買盤衝力。只要價格行為在任何短暫回調中嚴格守住這一轉換需求錨點，最小阻力路徑將高度傾斜於向更高的主導供給目標方向持續上行拓展。

平均時限：約兩週。

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at [this link](#) or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."